The Clinical Research Unit (CRU) is critical to the conduct of clinical research at the Abramson Cancer Center (ACC). This core is a centralized administrative unit that coordinates protocol management, budget and financial analysis, regulatory affairs expertise, research nursing support, and data management for therapeutic clinical trials conducted by ACC investigators. The CRU supports peer-reviewed funded clinical research projects, invesfigator-initiated clinical trials, cooperative group trials, and industry-sponsored trials. All trials supported by the CRU are approved by the ACC Clinical Trials Scientific Review and Monitoring Committee and are subject to ACC Data and Safety Monitoring Committee internal audits. By providing the necessary infrastructure for the transfer of preclinical discoveries into the clinic, this core is central to the ACC mission to support translational research and high impact clinical trials. The availability of a senior scientific leader, who is an expert in clinical trials management, as well as highly skilled research personnel, allows ACC clinical invesfigators to develop and conduct a comprehensive range of clinical trials for all types of cancer that involve both novel agents and innovative treatment approaches. In response to the 2004 CCSG critique ofthe CRU, the ACC has implemented Velos eResearch, a clinical trials management system. This information system will improve efficiency of CRU operations and ensure data standardization and regulatory compliance. Additional changes in the clinical research infrastructure have enhanced the function of this core. These include the establishment of disease-specific research groups charged with the responsibility of managing their portfolio of clinical trials, based upon scienfific goals and available resources; the establishment ofthe Strategic Planning and Resource Committee, a centralized group that reviews a proposed protocol to be certain that adequate resources are available to support the trial and that the budget is appropriate. These additional reviews help assure that the resources ofthe CRU are focused on the highest priority clinical trials conducted by ACC members. From 1/2009 to 12/2009 49 new therapeutic clinical trials have been activated by the CRU. CCSG support represents 20% ofthe core's proposed budget with the remaining funding coming from other grants/contracts and institutional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593284
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$458,731
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Acosta, Jonuelle; Wang, Walter; Feldser, David M (2018) Off and back-on again: a tumor suppressor's tale. Oncogene 37:3058-3069
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Rosenfeld, Aaron M; Meng, Wenzhao; Chen, Dora Y et al. (2018) Computational Evaluation of B-Cell Clone Sizes in Bulk Populations. Front Immunol 9:1472
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571

Showing the most recent 10 out of 1047 publications